Navigation Links
No Benefit Seen in Extending Herceptin for Breast Cancer
Date:12/7/2012

FRIDAY, Dec. 7 (HealthDay News) -- For women with a specific type of breast cancer, taking Herceptin for a year after initial treatment is just as effective -- and safer -- than staying on it for a longer period, new research suggests.

Many of the women in the study, who had HER2-postive early stage breast cancer, were cancer-free eight years later and experienced no major heart problems, the international study on Herceptin (trastuzumab) found.

"Giving trastuzumab for [two years] did not improve disease-free or overall survival, compared with one year of trastuzumab treatment," study author Dr. Martine Piccart, president of the European Society for Medical Oncology and chairwoman of the Breast International Group, said in a news release from the American Association for Cancer Research.

The study was run by the Breast International Group and Roche, the maker of Herceptin.

HER2-positive cancers are a particularly aggressive form of the disease and occur in 20 percent of breast cancer diagnoses, according to the U.S. National Cancer Institute.

The new phase 3 trial involved more than 5,000 women from several countries. After completing initial treatment for their early stage HER2-positive breast cancer, the women were randomly assigned to received Herceptin every three weeks for one year, two years or not at all.

Although the two-year treatment was no more effective than one year, heart problems occurred more frequently among the women who received Herceptin for the longer period. Most of the heart problems were reversible when the treatment was stopped, the researchers said.

The study proved "that a significant proportion of patients treated with trastuzumab ... are alive and free of disease recurrence after a median follow-up of eight years," said Piccart, who is chief of the medicine department at the Jules Bordet Institute in Brussels, Belgium.

"It is also reassuring with regard to the low cardiac toxicity of trastuzumab when given after adjuvant chemotherapy," she added. "Finally, it confirms that one year of adjuvant trastuzumab should remain the standard of care in women with HER2-positive early breast cancer."

The research was scheduled for Friday presentation at the 2012 San Antonio Breast Cancer Symposium. The data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information

The U.S. Centers for Disease Control and Prevention has more about breast cancer treatment.

-- Mary Elizabeth Dallas

SOURCE: American Association for Cancer Research, news release, Dec. 7, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Tafamidis: Approval denotes proven added benefit
2. Heart failure patients with diabetes may benefit from higher glucose levels
3. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
4. Avastin No Benefit to Older Lung Cancer Patients: Study
5. Talking to Yourself Could Have Mental Benefits
6. Study examines benefit of follow-up CT when abdominal ultrasound inconclusive
7. Research examines when benefits of screening mammography outweigh the harms for women in their 40s
8. Study finds that patient education videos viewed before an operation may benefit patients
9. Everyday fish oil capsule may provide kidney-related benefits
10. Erectile dysfunction drug may benefit cardiac function in young patients with heart defects
11. Study shows benefit of new maintenance therapy for multiple myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
No Benefit Seen in Extending Herceptin for Breast Cancer
(Date:2/23/2017)... ... ... The 89th Academy Awards will be celebrated this weekend, which means it’s ... Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” to the shoddiest ... for American Progress (CAP), for its report, Lessons From State Performance on NAEP: Why ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, ... be participating in Rare Disease Day events, hosted by the Rare Disease Legislative ... Report, a website, weekly e-newsletter and quarterly publication, will be conducting interviews with ...
(Date:2/23/2017)... ... 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. ... Not to Hot,” which will begin airing on February 24, 2017. The show chronicles ... the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series from ...
(Date:2/23/2017)... Lawn, NJ (PRWEB) , ... February 23, 2017 ... ... specializing in thought leadership , media relations, content marketing, social media management, ... With several clients already in the state and in nearby New Hampshire, Massachusetts ...
(Date:2/23/2017)... Angeles, California (PRWEB) , ... February 23, 2017 ... ... Global Sports Development will host a diverse symposium on “Doping in ... of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will be ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Feb 23, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Menopause market? ...
(Date:2/23/2017)... Research and Markets has announced the addition ... report to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and ... global Fibromyalgia market. The research answers the following questions: ... Fibromyalgia and their clinical attributes? How are they positioned in the ...
(Date:2/23/2017)... 2017 Obese people are seldom ... varicose veins in their body. The rising number of ... adoption of endovenous laser therapy for treatment of varicose ... therapy market, published by Future Market Insights, indicates ... consequences of obesity have collectively factored the growth in ...
Breaking Medicine Technology: